The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Ocular Hypertension

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ocular Hypertension


Psychiatry related information on Ocular Hypertension


High impact information on Ocular Hypertension

  • POAG caused by DCV at MYOC has been termed "myocilin glaucoma". Clinically, DCV at MYOC may manifest as a typical POAG, normal tension glaucoma, or ocular hypertension without glaucoma [8].
  • MEK1 gene transfer into RGCs markedly increased neuronal survival: 1366 +/- 70 RGCs/mm(2) (mean +/- SEM) were alive in the dorsal retina at 5 weeks after ocular hypertension surgery, a time when only 680 +/- 86 RGCs/mm(2) of these neurons remained in control eyes [9].
  • Also, although GPX activity increased after 10 weeks of ocular hypertension, GSH levels significantly decreased at 6 weeks of treatment with hyaluronic acid [10].
  • Dorzolamide and brinzolamide are two topical CA inhibitors which are currently available to treat ocular hypertension and/or glaucoma [11].
  • The most effective combined therapy regimen of MK801 and LY354740 was then assessed in a chronic ocular hypertension (OHT) rat model with application at 0, 1, and 2 weeks after OHT surgery and the effects assessed as described before [12].

Chemical compound and disease context of Ocular Hypertension


Biological context of Ocular Hypertension


Anatomical context of Ocular Hypertension


Gene context of Ocular Hypertension


Analytical, diagnostic and therapeutic context of Ocular Hypertension


  1. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Jonas, J.B., Kreissig, I., Degenring, R. Progress in retinal and eye research. (2005) [Pubmed]
  2. Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans. Gandolfi, S.A., Vecchi, M. Invest. Ophthalmol. Vis. Sci. (1996) [Pubmed]
  3. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Moroi, S.E., Gottfredsdottir, M.S., Schteingart, M.T., Elner, S.G., Lee, C.M., Schertzer, R.M., Abrams, G.W., Johnson, M.W. Ophthalmology (1999) [Pubmed]
  4. Steroid-induced ocular hypertension in patients with filtering blebs. Wilensky, J.T., Snyder, D., Gieser, D. Ophthalmology (1980) [Pubmed]
  5. Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. Oka, T., Tamada, Y., Nakajima, E., Shearer, T.R., Azuma, M. J. Neurosci. Res. (2006) [Pubmed]
  6. Risk assessment in the management of patients with ocular hypertension. Weinreb, R.N., Friedman, D.S., Fechtner, R.D., Cioffi, G.A., Coleman, A.L., Girkin, C.A., Liebmann, J.M., Singh, K., Wilson, M.R., Wilson, R., Kannel, W.B. Am. J. Ophthalmol. (2004) [Pubmed]
  7. Memantine. Merz. Kilpatrick, G.J., Tilbrook, G.S. Current opinion in investigational drugs (London, England : 2000) (2002) [Pubmed]
  8. Genetic dissection of myocilin glaucoma. Gong, G., Kosoko-Lasaki, O., Haynatzki, G.R., Wilson, M.R. Hum. Mol. Genet. (2004) [Pubmed]
  9. Activation of the extracellular signal-regulated kinase 1/2 pathway by AAV gene transfer protects retinal ganglion cells in glaucoma. Zhou, Y., Pernet, V., Hauswirth, W.W., Di Polo, A. Mol. Ther. (2005) [Pubmed]
  10. Retinal oxidative stress induced by high intraocular pressure. Moreno, M.C., Campanelli, J., Sande, P., Sánez, D.A., Keller Sarmiento, M.I., Rosenstein, R.E. Free Radic. Biol. Med. (2004) [Pubmed]
  11. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Sugrue, M.F. Progress in retinal and eye research. (2000) [Pubmed]
  12. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Guo, L., Salt, T.E., Maass, A., Luong, V., Moss, S.E., Fitzke, F.W., Cordeiro, M.F. Invest. Ophthalmol. Vis. Sci. (2006) [Pubmed]
  13. Effect of timolol maleate on the retinal circulation of human eyes with ocular hypertension. Grunwald, J.E. Invest. Ophthalmol. Vis. Sci. (1990) [Pubmed]
  14. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Orzalesi, N., Rossetti, L., Invernizzi, T., Bottoli, A., Autelitano, A. Invest. Ophthalmol. Vis. Sci. (2000) [Pubmed]
  15. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. WoldeMussie, E., Ruiz, G., Wijono, M., Wheeler, L.A. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  16. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Gudmundsdóttir, E., Stefánsson, E., Bjarnadóttir, G., Sigurjónsdóttir, J.F., Gudmundsdóttir, G., Masson, M., Loftsson, T. Invest. Ophthalmol. Vis. Sci. (2000) [Pubmed]
  17. Delayed secondary glucocorticoid responsiveness of MYOC in human trabecular meshwork cells. Shepard, A.R., Jacobson, N., Fingert, J.H., Stone, E.M., Sheffield, V.C., Clark, A.F. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  18. Mechanisms of action of unoprostone on trabecular meshwork contractility. Thieme, H., Stumpff, F., Ottlecz, A., Percicot, C.L., Lambrou, G.N., Wiederholt, M. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  19. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. Rudzinski, M., Wong, T.P., Saragovi, H.U. J. Neurobiol. (2004) [Pubmed]
  20. Results of the betaxolol versus placebo treatment trial in ocular hypertension. Kamal, D., Garway-Heath, D., Ruben, S., O'Sullivan, F., Bunce, C., Viswanathan, A., Franks, W., Hitchings, R. Graefes Arch. Clin. Exp. Ophthalmol. (2003) [Pubmed]
  21. Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans. Kanno, M., Araie, M., Koibuchi, H., Masuda, K. The British journal of ophthalmology. (2000) [Pubmed]
  22. Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol. Steigerwalt, R.D., Laurora, G., Belcaro, G.V., Cesarone, M.R., De Sanctis, M.T., Incandela, L., Minicucci, R. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2001) [Pubmed]
  23. Effect of dipyridamole on prostaglandin-induced ocular hypertension in rabbits. Podos, S.M. Invest. Ophthalmol. Vis. Sci. (1979) [Pubmed]
  24. Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage. Pang, I.H., Johnson, E.C., Jia, L., Cepurna, W.O., Shepard, A.R., Hellberg, M.R., Clark, A.F., Morrison, J.C. Invest. Ophthalmol. Vis. Sci. (2005) [Pubmed]
  25. Nerve fiber layer and optic disc fluorescein defects in glaucoma and ocular hypertension. Nanba, K., Schwartz, B. Ophthalmology (1988) [Pubmed]
  26. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the possible involvement of STAT3 pathway. Ji, J.Z., Elyaman, W., Yip, H.K., Lee, V.W., Yick, L.W., Hugon, J., So, K.F. Eur. J. Neurosci. (2004) [Pubmed]
  27. Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension. Giasson, C.J., Nguyen, T.Q., Boisjoly, H.M., Lesk, M.R., Amyot, M., Charest, M. Am. J. Ophthalmol. (2000) [Pubmed]
  28. Prognostic value of HLA-A 3, BW 35, B 7, and B 12 in ocular hypertension. Becker, B., Shin, D.H. Int. Arch. Allergy Appl. Immunol. (1977) [Pubmed]
  29. Alterations in neurofilament light in optic nerve in rat kainate and monkey ocular hypertension models. Taniguchi, T., Shimazawa, M., Hara, H. Brain Res. (2004) [Pubmed]
  30. The renin-angiotensin system in the rabbit eye. Ramirez, M., Davidson, E.A., Luttenauer, L., Elena, P.P., Cumin, F., Mathis, G.A., De Gasparo, M. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (1996) [Pubmed]
  31. Study of central regulation of intraocular pressure using ventriculocisternal perfusion. Liu, J.H., Neufeld, A.H. Invest. Ophthalmol. Vis. Sci. (1985) [Pubmed]
  32. Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily. Wandel, T., Fishman, D., Novack, G.D., Kelley, E., Chen, K.K. Ophthalmology (1988) [Pubmed]
  33. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%. McCarey, B.E., Kapik, B.M., Kane, F.E. Ophthalmology (2004) [Pubmed]
  34. Timolol gel versus acetazolamide in the prophylaxis of ocular hypertension after phacoemulsification. Kanellopoulos, A.J., Perry, H.D., Donnenfeld, E.D. Journal of cataract and refractive surgery. (1997) [Pubmed]
WikiGenes - Universities